Literature DB >> 16046825

Cardiovascular damage in Alzheimer disease: autopsy findings from the Bryan ADRC.

Elizabeth H Corder1, John F Ervin, Evelyn Lockhart, Mari H Szymanski, Donald E Schmechel, Christine M Hulette.   

Abstract

Autopsy information on cardiovascular damage was investigated for pathologically confirmed Alzheimer disease (AD) patients (n=84) and non-AD control patients (n=60). The 51 relevant items were entered into a grade-of-membership model to describe vascular damage in AD. Five latent groups were identified "I: early-onset AD," "II: controls, cancer," "III: controls, extensive atherosclerosis," "IV: late-onset AD, male," and "V: late-onset AD, female." Expectedly, Groups IV and V had elevated APOE epsilon 4 frequency. Unexpectedly, there was limited atherosclerosis and frequent myocardial valve and ventricular damage. The findings do not indicate a strong relationship between atherosclerosis and AD, although both are associated with the APOE epsilon 4. Instead, autopsy findings of extensive atherosclerosis were associated with possible, not probable or definite AD, and premature death. They are consistent with the hypothesis that brain hypoperfusion contributes to dementia, possibly to AD pathogenesis, and raise the possibility that the APOE allele epsilon 4 contributes directly to heart valve and myocardial damage.

Entities:  

Year:  2005        PMID: 16046825      PMCID: PMC1184050          DOI: 10.1155/JBB.2005.189

Source DB:  PubMed          Journal:  J Biomed Biotechnol        ISSN: 1110-7243


INTRODUCTION

It is well known that Alzheimer's disease (AD) is the most common form of senile dementia in the US and Europe. Population studies suggest that 47% of persons over age 85 are affected [1, 2, 3]. The established genetic risk factor is the E4 isoform for the lipid transport molecule apolipoprotein E (APOE: gene; ApoE: protein) [4, 5, 6, 7, 8, 9, 10] which is also a risk factor for coronary atherosclerosis [11, 12, 13, 14, 15, 16, 17, 18, 19]. The ϵ4 allele for APOE has sometimes been implicated in vascular dementia (VaD) and stroke [20, 21, 22], the second most common form of senile dementia. Previous studies have shown decreased smooth muscle actin in brain blood vessels of AD patients when compared to nondemented controls [23]. Possibly, more extensive amyloid deposition in heart and brain vessels determines the 5-fold worse prognosis (8% compared to 40% mortality) within three months following a diagnosis of heart disease or stroke at ages 85+ for ϵ3/4+ persons, compared to ϵ2/3+ [24], and largely accounts for reduced ϵ4, and elevated ϵ2, frequencies found among centenarians [25]. The role of cardiovascular damage in the development of AD is consistent with a number of existing reports in the literature, although few deal with pathologically confirmed AD and pathologic cardiovascular findings in age-matched samples. Certainly, cardiovascular damage is common among subjects with neuropathologically confirmed AD [26, 27]. Hypertension has been suggested as a risk factor for subsequent AD, normal or low blood pressure at the end stages of the disease [28, 29, 30, 31, 32]. Skoog et al [31] investigated a population cohort and found an association between elevated blood pressure at age 70 years and the development of dementia 10 to 15 years later. They hypothesized that hypertension causes hyalinization of the vessel walls in the brain and hypoperfusion in the deep white matter. Atherosclerotic disease and silent myocardial infarcts have been associated with cognitive impairment [26, 27]. In the Rotterdam study [33], the extent of atherosclerosis was assessed by ultrasonography of the carotid arteries and by the ratio of ankle to brachial systolic blood pressure. Subjects were scored from 0 to 3, from no to severe, atherosclerosis. The odds of a clinical AD diagnosis increased 2-fold with the extent of atherosclerosis, 3-fold for VaD. Autopsy studies are limited, but suggest that cardiovascular disease contributes to the expression of dementia for patients who exhibit Alzheimer neuropathologic changes. Sparks et al [28] showed that significant coronary artery disease was present in 90% (19 of 21) of AD patients undergoing a complete postmortem examination. Patients with peripheral vascular disease, cerebrovascular accidents, and myocardial infarcts had lower antemortem cognitive scores on the minimental state exam [27]. Patients with end-stage renal disease have cognitive impairment thought to be due to multiinfarct dementia [34]. However, Irina et al [35] did not find a correlation of dementia or pathologically confirmed AD with pathologic cardiovascular index (CVI), that is, the extent of atherosclerosis in the brain and periphery combined with evidence of cardiovascular lesions and cardiomegaly. Specifically, the CVI was higher for 103 nondemented subjects compared to 106 demented subjects, 9.2 versus 7.5 out of a possible 15 (P < .05). Mean CVI was 5.2 for subjects meeting CERAD criteria for possible AD, 7.3 for definite AD, increasing to 8.5 for vascular and mixed dementia. Thus atherosclerosis was associated with VaD, not the extent of Alzheimer's lesions (associated with the ϵ4 allele for APOE). To clarify the role of cardiovascular disease in dementia, we investigated 144 subjects prospectively enrolled in the Bryan Alzheimer Disease Research Center Rapid Autopsy Program at Duke University who had had complete body autopsies.

METHODS

The rapid autopsy program

The Rapid Autopsy Program of the Bryan Alzheimer Disease Research Center has been in continuous existence since 1985 [36]. Recruitment, enrollment, and autopsy procedures have been approved by the Institutional Review Board. After receiving informed consent from the patients and their families, both demented and nondemented control donors are enrolled and followed prospectively until death. While the principal purpose of the program is to retrieve and bank human brain tissue for use in research, many donors have consented to complete diagnostic autopsy. At the time of death, consent for autopsy is again obtained according to Duke University Medical Center regulations. Autopsy is performed in the usual fashion with examination of all body organs and cavities. Autopsies are performed in compliance with Centers for Disease Control precautions against the spread of infectious diseases [37, 38].

Data abstraction

APOE genotype (for 46 demented and 38 nondemented subjects) was obtained from existing databases. We abstracted the 144 autopsy records to obtain information on dementia status, cardiovascular disease, medical diagnoses, and organ weights. An Excel spreadsheet was used as the abstract form. Abstraction was done independently by two persons. Inconsistencies were resolved by consensus among the authors. The 51 items are listed in Tables 1–3, respectively.
Table 1

The clinical variables.

NoVariableDescription

1Dementia0 = no, 1 = yes (ie, age at onset listed)
2Dementia status0 = normal, 1 = dementia, 2 = normal cognition,
3 = disease control, 4 = early dementia,
6 = Parkinson's disease (PD)
3Final diagnosis0 = normal, 1 = AD, 2 = PD, 3 = possible AD, 4 = not listed
4Age at onset0 = not demented, 1 ≤ 60 years of age, 2 = 60–70, 3 = 70–80, 4 = 80+
5Duration of dementia0 = normal, 1 ≤ 5 years, 2 = 5–10, 3 = 10–15, 4 = 15+
6Age at death1 ≤ 60 years, 2 = 60–70, 3 = 70–80, 4 = 80+
7Sex0 = male, 1 = female
8Race0 = white, 1 = black
9Body mass index0 = 8–17.9, 1 = 17.9–21.2, 2 = 21.2–25.0, 3 = 25+, 9 = missing
10Cancer diagnosis0 = no, 1 = yes
11Respiratory system infection0 = no, 1 = yes
12Urinary system infection0 = no, 1 = yes
13Digestive system infection0 = no, 1 = yes
14APOE genotype 0 = ϵ22, 1 = ϵ23, 2 = ϵ33, 3 = ϵ24, 4 = ϵ34, 5 = ϵ44
Table 3

The quartiles for organ weights.

NoVariableDescription

45Heart0 ≤ 295 gm, 1 = 295–351, 2 = 351–412, 3 = 412+, 9 = missing
46Lungs (mean)0 ≤ 316 gm, 1 = 316–443, 2 = 443–585, 3 = 585+, 9 = missing
47Liver0 ≤ 880 gm, 1 = 880–1100, 2 = 1100 1140, 3 = 1140+, 9 = missing
48Kidneys (mean)0 ≤ 99 gm, 1 = 99–125, 2 = 125–153, 3 = 153+, 9 = missing
49Spleen0 ≤ 75 gm, 1 = 75–113, 2 = 113–170, 3 = 170+, 9 = missing
50Adrenals (mean)0 ≤ 6.95 gm, 1 = 6.95–8.1, 2 = 8.1–10.2, 3 = 10.2+, 9 = missing
51Thyroid0 ≤ 9.25 gm, 1 = 9.25–14, 2 = 14–20, 3 = 20+, 9 = missing

The statistical approach

Detailed clinical profiles were identified using a statistical technique called grade-of-membership analysis or GoM [39, 40]. Use of univariate approaches would necessarily have low power at this sample size, especially if corrected for multiple comparisons (not needed when all variables are jointly examined). An additional advantage is that each variable can be understood in relation to all the other variables allowing a clinical narrative, something like the process of diagnosis, to be achieved for the identified latent model-based groups. GoM can be described after first identifying four indices. One is the number of subjects I (i = 1,2,..., I). Here I = 144 subjects were identified. The second index is the number of variables J (j = 1, 2,..., J). There are J = 50 variables each representing one of the clinical variables described above. Our third index is Lj: the set of response levels for the Jth variable. This leads to the definition of the basic GoM model where the probability that the ith subject has the Ljth level of the Jth variable is defined by a binary variable (ie, y = 0,1). The model with these definitions is where the g are convexly constrained scores (ie, 0.0 ≤ g ≤ 1.0;∑ g = 1.0 ) for subjects and the λ are probabilities that, for the Kth latent group, the Ljth level is found for the Jth variable. The procedure thus uses this expression to identify K profiles representing the pattern of J × Lj responses found for I subjects. The parameters g and λ are estimated simultaneously using the likelihood function (in its most basic form) [39, 40]. In the likelihood y is 1.0 if the Ljth level is present and 0.0 if it is not present. GoM models specifying from K = 3–5 groups, that is, clinical profiles, were constructed. The significance of adding the K + 1 profile was tested as an independent increment in the fit of the model adjusting for the larger number of degrees of freedom in the larger model. Akaike information criterion [41] was calculated as where l is the likelihood value and P is the number of estimated parameters. However, for parameters on the boundary, that is, value = 0, only one is penalized. The rationale for subtracting only one for parameters on the boundary is that the distribution for those parameters is (1/2)X2 (central). The lowest value of the AIC designates the best model, that is, the model with the best fit and least bias. GoM models specifying either 3, 4, 5, or 6 clinical profiles, that is, K = 3–6, had AIC = −1503, −1647, −1703, and −1678, respectively. The 5-group model is reported. Information on APOE genotype was not used to construct the groups used to clinically characterize the subjects. One option in the likelihood is to separate calculations for “internal” (here, clinical) and “external” (here, APOE genotype) variables. For internal variables, MLE of g and λ are generated and the information in internal variables is used to define the K groups. For external variables the likelihood is evaluated (and MLE of λ; generated) but the information is not used to redefine the K groups, that is, the likelihood calculations for likelihood equations involving the g are disabled for external variables so that the g, and the definition of the K groups, is not changed.

RESULTS

Overview

Five model-based groups best represented the autopsy information on diagnoses, cardiovascular disease, and organ weights. They are labeled I, II, III, IV, and V ordered according to increasing age at the time of death. Each group is defined by the probabilities of response for the many variables, akin to the frequencies found in the sample as a whole. Tables 4–6 describe the profiles in terms of diagnoses, cardiovascular damage, and organ weights, respectively. Not all the variables described in Tables 1–3 are shown in the tables of results.
Table 4

Clinical variable frequencies for each group. Each model-based group is defined by the probabilities of being demented & probabilities of response for the other variables, that is, the model λ parameters.

VariableResponseGroup
N = 36.4N = 21.3N = 27.2N = 27.5N = 31.5
IIIIIIIVV

DementedYes (%)10000100100

Age at onset< 60 years8170
60–70153553
70–8044634
80+01213

Duration of dementia< 5 years1250
5–1038620
10–15433337
15+7063

Age at death< 602020000
60–707301200
70–80773683112
80+07206988

SexFemale6620350100

BMI (km/m2)8–17.96700423
17.9–21.211003754
21.2–25.01341175114
25+10598399

Cancer diagnosisYes24840600

Respiratory infectionYes69708257100

Urinary tract infectionYes1616272944

Digestive tract infectionYes200223054
Table 6

Organ weights for each group. The model-based groups are defined by the probabilities response for the variables, here represented on a semiquantitative scale: “++++“ denotes the highest quartile of weight, while “+++,” “++,” and “+” denote the respectively lower quartiles.

OrganGroup
IIIIIIIVV

Heart+++++++++++++
Lungs++++++++++++
Liver+++++++++++++++
Kidneys++++++++++++++
Spleen+++++++++++++
Adrenals++++++++++++++
Thyroid+++++++++++++++
The size of the groups was similar (Table 4). The sizes are the summed memberships of individuals in the respective groups either partial, that is, fractional, or complete, that is, contributing size one to the sum, depending on the extent of resemblance of the individual to the group. Group I was the largest group (n = 36.4) and Group II was the smallest (n = 21.3). The prevalence of demented and nondemented subjects, that is, sum of memberships, in each model-based group is shown in Table 7, as well as the distribution of APOE frequencies across the model-based groups.
Table 7

Distribution of subjects across the groups, subdivided according to dementia status and APOE genotype; ϵ2/2 and ϵ/2/3 were grouped with ϵ3/3; ϵ2/4 and ϵ4/4 were grouped with ϵ3/4. The sizes are the sums of the model g parameters, that is, the memberships of individuals in the groups, whole or partial.

SubjectsGroup
IIIIIIIVVAll

Demented30.92.38.519.722.684
Not demented5.519.018.77.89.060

ϵ3/3+Demented4.002.03.95.015
Normal2.49.18.62.23.626

ϵ4/4Demented12.31.03.28.26.231
Normal1.63.53.81.51.511

Total36.421.327.227.531.5144

Dementia diagnoses

Next observe that the groups were either demented or not demented (Table 4): Groups I, IV, and V had 100% probability of dementia while Groups II and III were not demented. There was high probability that dementia was specifically due to AD: 81% for Group I, 73% for Group IV, and 72% for Group V. Otherwise, no explanatory diagnosis was given for the dementia for these groups. Groups II and III had no chance of an AD diagnosis. However, possible AD was sometimes found in the nondemented groups, 9% for Group II and 43% for Group III (5–10 years younger than Groups IV and V). Group II had a 22% chance of being a so-called “disease control” and Group III had a 10% chance of having Parkinson's disease. The dementia status and final diagnoses variables are described in Table 2.
Table 2

The cardiovascular variables.

NoVariableDescription

15Pericardial cavity fluid0 ≤ 10 mL, 1 = 11–50, 2 = 51–100, 3 ≥ 100, 9 = missing
16Right pleural cavity fluid0 ≤ 10 mL, 1 = 11–50, 2 = 51–100, 3 ≥ 100, 9 = missing
17Left pleural cavity fluid0 ≤ 50 mL, 1 = 51–200, 2 = 201–500, 3 ≥ 500, 9 = missing
18Peritonial fluid0 ≤ 50 mL, 1 = 51–200, 2 = 201–500, 3 ≥ 500, 9 = missing
19Aorta atherosclerosis0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
20Right coronary artery atherosclerosis0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
21Right coronary artery narrowing0 = normal, 1 = 5%–25%, 2 = 26%–75%, 3 ≥ 75%, 9 = missing
22Right coronary artery calcification0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
23Left main coronary artery atherosclerosis0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
24Left main coronary artery narrowing0 = normal, 1 = 5%–25%, 2 = 26%–75%, 3 ≥ 75%, 9 = missing
25Left main coronary artery calcification0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
26Circumflex branch atherosclerosis0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
27Circumflex branch narrowing0 = normal, 1 = 5%–25%, 2 = 26%–75%, 3 ≥ 75%, 9 = missing
28Circumflex branch calcification0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
29Anterior descending branch atherosclerosis0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
30Anterior descending branch narrowing0 = normal, 1 = 5%–25%, 2 = 26%–75%, 3 ≥ 75%, 9 = missing
31Anterior descending branch calcification0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
32Right atrial cavity dilation0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
33Right atrial wall thickness0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
34Right ventricular cavity dilation0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
35Right ventricular wall thickness0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
36Left atrial cavity dilation0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
37Left atrial wall thickness0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
38Right ventricular cavity dilation0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
39Right ventricular wall thickness0 = normal, 1 = mild, 2 = moderate, 3 = severe, 9 = missing
40Aortic valve0 = normal, 1 = abnormal, 9 = missing
41Tricuspid valve0 = normal, 1 = abnormal, 9 = missing
42Pulmonic valve0 = normal, 1 = abnormal, 9 = missing
43Mitral valve0 = normal, 1 = abnormal, 9 = missing
44Ventricular myocardium0 = normal, 1 = abnormal, 9 = missing

Onset age, sex, and dementia duration

As the age at the onset of dementia for Group I was usually before age 65, Group I represents early-onset AD. Groups IV (male) and V (female) represent late-onset AD: the mean age at onset was around 70 years of age for both groups, marginally earlier for female Group V compared to male Group IV. Nonetheless Group V had longer disease duration and an older age at the time of death. The 2% of the sample that was black was concentrated in the control Groups II and III (not shown).

BMI and nonneurologic diagnoses

Early-onset dementia (I) was associated with extremely low body mass index (BMI). Women with late-onset dementia and long dementia duration (V) also had very BMI. Cancer was a common diagnosis for Group II, absent for Group III. Men with late onset dementia also frequently had cancer (IV), absent for female Group V. Respiratory and urinary infections were common for each group especially for demented women (V). Digestive tract infections were not found for Group II (cancer).

Cardiovascular disease

There was little evidence of cardiovascular disease for the early-onset relatively young Group I. Control Group II with cancer uniquely often had pulmonary effusions, ascites, and a moderately dilated right ventricle. Groups II–V had minimal amounts of pericardial cavity fluid, absent for Group I (not shown). Control Group III without cancer had severe atherosclerosis with narrowing and calcification in the aorta and each of the major coronary vessels—right coronary artery, left main coronary artery, circumflex branch, and anterior descending branch. The extent of athersclerosis was usually similar for each vessel. Table 5 represents the average over all the coronary vessels. Group III with extensive atherosclerosis often also had moderate atrial dilation and moderately thickened ventricular myocardium (not shown).
Table 5

Cardiovascular damage for each group. The model-based groups are defined by the probabilities response for the variables sometimes represented on a semiquantitative scale: “+++” denotes severe, while “++,” “+,” and “−” denote moderate, mild, and the absence of lesions; “++/−” denotes mixture of moderate and absent; “+/−” denotes mixture of mild and absent; “++/+” denotes a mixture of moderate and mild; “+++/−” denotes a mixture of severe and absent. *means the average of right coronary artery, left main coronary artery, circumflex branch, and anterior descending branch.

OutcomeLocationGroup
IIIIIIIVV

FluidPeritoneal cavity+++/−+/−
Pleural cavity++++/−

Coronary artery*Atherosclerosis+/−++++++
Narrowing+/−++++++
Calcification+/−++++++

AortaAtherosclerosis+/−+++++++++/+

DilationRight atrium+/−++/−++++
Right ventricle+/−++/−+/−++
Left atrium+/−+/−+/−+/−
Left ventricle+/−+++/−

DamageAortic valve2010033
Mitral valve143210045
Pulmonic valve3714
Tricuspid valve1936417
Ventricular myocardium4946
Atherosclerosis was unexpectedly less extensive for demented Groups IV and V, limited for Group II, and absent for Group I. Aortic and mitral valve damage and evidence of ischemic damage to the left ventricular myocardium were common for male late-onset dementia Group IV, and also female Group V. Both of the late-onset dementia groups and Group III had a moderately dilated right atrium.

Organ weights

Generally speaking, the organ weights shown in Table 6 paralleled the BMI results shown in Table 4. Nonetheless there were some interesting departures: organ weights were preserved for Group I having the lowest BMI. The low heart weight for this relatively young group is consistent with limited heart damage, as indicated by Table 4. Lung weight was highest for Group II, which often had pulmonary edema and pleural effusions. Group III, most affected by atherosclerosis, had the highest heart weight. Compared to Group III, organ weights and BMI were lower for Group IV. Very low BMI and weight for most organs was found for late-onset dementia Group V, females with long dementia duration. Notably, both late-onset dementia groups had low thyroid weight compared to the early-onset and control groups.

APOE genotype

APOE genotype data was available on a subset of 84 subjects, 46 with dementia and 38 controls. Although this information was not used to predict the groups, individuals carrying the ϵ4 allele were more common in the dementia groups. The summed memberships of individuals of each genotype are shown in Table 7. As individuals, the study subjects who exactly resembled a single profile contributed one to the size of the relevant profile and zero to the other profiles. Otherwise, the subject contributed a total of one to the sizes of the relevant profiles depending on the extent of resemblance. In contrast to results, Tables 4– 6 that predict frequencies for persons exactly like the group, Table 7 demonstrates that as individuals there was overlap of demented and nondemented subjects in the groups, not surprisingly given the many variables used to construct the groups, frequent comorbidity at advanced ages, and differences from individual to individual.

DISCUSSION

We investigated cardiovascular damage found for 84 demented and 60 nondemented subjects enrolled in the Bryan ADRC Rapid Autopsy Program. The subjects could be represented by five distinct latent groups based on detailed pathologic information. The late-onset AD groups, both male (IV) and female (V), had frequent heart valve damage, evidence of ischemic damage to the left ventricular myocardium, low BMI, and low organ weights notably including the thyroid gland. They did not have extensive atherosclerosis compared to control subjects without cancer (III), many of whom had possible AD. In particular, the female group (V) having long AD duration had little atherosclerosis. Control subjects with cancer (II) had little atherosclerosis or valve damage. Instead, pulmonary edema and ascites were common. The early-onset AD group (I) had little cardiovascular damage, with normal organ weights despite low body weight. The finding of mitral and aortic valve damage, and evidence of ischemic damage to the left ventricular myocardium for the AD groups, especially among men, is interesting. It is consistent with the hypothesis that brain hypoperfusion and microthrombi may contribute to the evolution of AD pathology or to the expression of dementia at an earlier stage in AD pathogenesis [40]. However, the AD groups (IV and V) were the oldest groups. Thus valve and myocardial damage might simply be age related and less rapidly fatal than extensive coronary atherosclerosis. Alternatively, the oldest cohorts in the sample may have valve damage resulting from rheumatic fever not treated with antibiotics. Assuming that mitral valve damage is related to rheumatic fever in the oldest subjects does not, however, rule out the possibility that it contributes to the expression of dementia by decreasing brain perfusion and, possibly, contributing to brain pathology. In addition, the lack of an age-matched control group requires comment. Since aging is itself a risk factor for valvular disease, an age-matched control group would be required to fully examine the hypothesis that hypoperfusion contributes to dementia. Unfortunately, this was not possible in this small-human-population-based study. Rigorous analysis must await examination of a larger cohort. Despite the caveats, the results on valve and myocardial damage are striking and the given frequent finding of the ϵ4 allele for APOE in the AD groups raises the possibility that ApoE directly damages these structures as it has been demonstrated to damage blood vessels [42, 43]. Muscle actin in the arterioles is replaced by amyloid for ϵ4/4+ subjects to a much greater extent than for ϵ3/3+ subjects. Meyer et al [44] (n = 36) found hypertrophy of the left ventricle (uncommon in the Bryan ADRC sample) in 9 of 19 (47%) ϵ3/4+ AD patients and only 1 of 11 (9%) ϵ3/3+ patients (χ22 = 3.8, df = 1, P = 0.05). There were no statistically significant differences in the presence of stenotic changes or calcification in aortic or mitral valvulae in this small sample. The study results tend to suggest that the 5-fold worse prognosis following a diagnosis of heart disease or stroke at ages 85+ for ϵ4+ persons may be due to impaired cerebrovascular function due to amyloid deposition [25]. Data presented here would also suggest that cardiovascular malfunction may be a contributing factor. The study does not support the notion that extensive atherosclerosis is a risk factor for definite AD. Instead, subjects with extensive atherosclerosis died before a diagnosis of probable or definite AD could be made. The relatively low ϵ4 frequency for control subjects with extensive atherosclerosis was unexpected since the allele carries a modestly increased risk of coronary atherosclerosis [13, 14, 15, 16, 17, 44]. There is also a small ecologic association between ϵ4 frequency and population rates of myocardial infarction in middle age [45, 46]. Nevertheless the findings from this study are consistent with the lack of risk for heart disease and stroke for ϵ4 found in the Kungsholmen Project for cohort age of 75 and older [25]. Atherosclerosis may possibly at least partially reverse itself during the clinical progression of AD as weight is lost and food intake diminished. This explanation is supported to some extent by the fact that possible AD was common in the nondemented group with high heart weight and extensive atherosclerosis. So that atherosclerosis might be a common concomitant of early or preclinical AD but may not be found at the time of death many years later. A strong feature of the study is that comparisons were made based on pathologic features and pathologically confirmed diagnoses. The data analytic approach was helpful in resolving the many items of information into a tractable number of distinct groups consistent with clinical experience, despite the relatively small sample size. For example, heart weight was highest for the group also having the most extensive athersosclerosis and lung weight was highest for the group also having pulmonary effusions and ascites. In summary, extensive coronary atherosclerosis at autopsy was associated with death at earlier ages and limited AD pathology. Pathologically confirmed AD was not associated with extensive coronary atherosclerosis. Surprisingly, it was associated with mitral and aortic valve damage and damage to the ventricular myocardium.
  43 in total

1.  Inherited frailty. ApoE alleles determine survival after a diagnosis of heart disease or stroke at ages 85+.

Authors:  E H Corder; H Basun; L Fratiglioni; Z Guo; L Lannfelt; M Viitanen; L S Corder; K G Manton; B Winblad
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

2.  Cognitive functional status of age-confirmed centenarians in a population-based study.

Authors:  M H Silver; E Jilinskaia; T T Perls
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2001-05       Impact factor: 4.077

3.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals.

Authors:  C M Hulette; K A Welsh-Bohmer; M G Murray; A M Saunders; D C Mash; L M McIntyre
Journal:  J Neuropathol Exp Neurol       Date:  1998-12       Impact factor: 3.685

4.  The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study.

Authors:  L U Gerdes; C Gerdes; K Kervinen; M Savolainen; I C Klausen; P S Hansen; Y A Kesäniemi; O Faergeman
Journal:  Circulation       Date:  2000-03-28       Impact factor: 29.690

5.  Expression of the apolipoprotein E gene does not affect motor recovery after sensorimotor cortex injury in the mouse.

Authors:  L B Goldstein; M P Vitek; H Dawson; S Bullman
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

6.  A simple and effective method for inactivating virus infectivity in formalin-fixed tissue samples from patients with Creutzfeldt-Jakob disease.

Authors:  P Brown; A Wolff; D C Gajdusek
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

7.  Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease.

Authors:  F M van Bockxmeer; C D Mamotte
Journal:  Lancet       Date:  1992-10-10       Impact factor: 79.321

8.  The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations.

Authors:  D M Hallman; E Boerwinkle; N Saha; C Sandholzer; H J Menzel; A Csázár; G Utermann
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

9.  Relation of coronary heart disease and apolipoprotein E phenotype in patients with non-insulin dependent diabetes.

Authors:  M Laakso; A Kesäniemi; K Kervinen; M Jauhiainen; K Pyörälä
Journal:  BMJ       Date:  1991-11-09

10.  Vascular smooth muscle actin is reduced in Alzheimer disease brain: a quantitative analysis.

Authors:  John F Ervin; Catherine Pannell; Mari Szymanski; Kathleen Welsh-Bohmer; Donald E Schmechel; Christine M Hulette
Journal:  J Neuropathol Exp Neurol       Date:  2004-07       Impact factor: 3.685

View more
  14 in total

1.  A Cross-Sectional Analysis of Late-Life Cardiovascular Factors and Their Relation to Clinically Defined Neurodegenerative Diseases.

Authors:  Brittany N Dugger; Michael Malek-Ahmadi; Sarah E Monsell; Walter A Kukull; Bryan K Woodruff; Eric M Reiman; Thomas G Beach; Jeffrey Wilson
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Jul-Sep       Impact factor: 2.703

2.  Apolipoprotein E gene polymorphism and allele frequencies in the Lebanese population.

Authors:  Rami A R Mahfouz; Amira S Sabbagh; Laila F Zahed; Ziyad R Mahfoud; Rana F Kalmoni; Zaher K Otrock; Ali T Taher; Ghazi S Zaatari
Journal:  Mol Biol Rep       Date:  2006-06       Impact factor: 2.316

Review 3.  The Role of Hypoxia-Inducible Factor 1 in Mild Cognitive Impairment.

Authors:  Osigbemhe Iyalomhe; Sabina Swierczek; Ngozi Enwerem; Yuanxiu Chen; Monica O Adedeji; Joanne Allard; Oyonumo Ntekim; Sheree Johnson; Kakra Hughes; Philip Kurian; Thomas O Obisesan
Journal:  Cell Mol Neurobiol       Date:  2016-11-17       Impact factor: 5.046

Review 4.  Atrial Fibrillation - A Common Ground for Neurology and Cardiology.

Authors:  Fawzi Abukhalil; Aakash Bodhit; Peter Y Cai; Saeed Ansari; Spandana Thenkabail; Sarah Ganji; Pradeepan Saravanapavan; Chandana Chandra Shekhar; Michael F Waters; Thomas M Beaver; Vishnumurthy Shushrutha Hedna
Journal:  J Atr Fibrillation       Date:  2013-08-31

5.  Cerebrovascular smooth muscle actin is increased in nondemented subjects with frequent senile plaques at autopsy: implications for the pathogenesis of Alzheimer disease.

Authors:  Christine M Hulette; John F Ervin; Yvette Edmonds; Samantha Antoine; Nicolas Stewart; Mari H Szymanski; Kathleen M Hayden; Carl F Pieper; James R Burke; Kathleen A Welsh-Bohmer
Journal:  J Neuropathol Exp Neurol       Date:  2009-04       Impact factor: 3.685

6.  Parkinson's disease and low frequency alleles found together throughout LRRK2.

Authors:  Coro Paisán-Ruiz; Nicole Washecka; Priti Nath; Andrew B Singleton; Elizabeth H Corder
Journal:  Ann Hum Genet       Date:  2009-05-21       Impact factor: 1.670

7.  Heart disease as a risk factor for dementia.

Authors:  B Ng Justin; Michele Turek; Antoine M Hakim
Journal:  Clin Epidemiol       Date:  2013-04-26       Impact factor: 4.790

8.  Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer's Disease.

Authors:  Thomas G Beach; Chera L Maarouf; Reed G Brooks; Scophil Shirohi; Ian D Daugs; Lucia I Sue; Marwan N Sabbagh; Douglas G Walker; LihFen Lue; Alex E Roher
Journal:  BMC Geriatr       Date:  2011-01-25       Impact factor: 3.921

9.  Parkinson's disease in relation to pesticide exposure and nuclear encoded mitochondrial complex I gene variants.

Authors:  Elizabeth H Corder; George D Mellick
Journal:  J Biomed Biotechnol       Date:  2006

10.  Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia.

Authors:  Jack C de la Torre
Journal:  Cardiovasc Psychiatry Neurol       Date:  2012-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.